Lamb Weston Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.12B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.7× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LW | VRTX | |
|---|---|---|
Market Cap | $7.12B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $529.65 |
52-Week Low | $38.48 | $376.62 |
Enterprise Value | $11.00B | $126.92B |
Dividend Yield | 2.93% | — |
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $52.27, up 0.42% today, with a bullish technical outlook and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and trades at a P/E of 25.13. Recent Q2 2026 results exceeded expectations with EPS of $0.87 versus $0.626 estimated. The company maintains a solid dividend yield with a recent $0.38 per share payout announced.
The outlook is positive given operational improvements and cost savings, though international headwinds and margin pressures pose risks. Analyst consensus is a 'Hold' with a $53.86 price target, indicating modest upside. Investors should weigh strong North American growth against geopolitical and cost challenges impacting international segments.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Trailing returns across standard periods
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →